Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. 10-Q filed Nov 5, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 20 added · 18 removed · 61 modified; 22 with only figures updated; 3 moved without change
-
Modified · Tariffs and Trade Protection Measures
Our business is subject to risks related to, among other factors, tariffs and other trade protection measures put in
theplace by theUnited StatesU.S. or other countries, as well as U.S. international trade relations, including those with China, Canada and the European Union. Starting in early 2025, theUnited StatesU.S. government announced additional tariffs on certain goods imported into the U.S. from numerous countries and multiple nations countered with reciprocal tariffs and other actions in response. While the final tariffs and other measures to be imposed, and their applicability to our business, remain uncertain, such actions may negatively impact demand and result in an increase in some product costs. We will continue to actively monitor the situation and evaluate actions that can be taken to moderate and/or minimize its effects, including seeking refunds related to prior tariff assessments where applicable. For further information regarding the impact of potential additional tariffs and trade protection measures on the Company, see Part I., Item 1A, Risk Factors in our 2025 Annual Report on Form 10-K.